UPDATE: Mikaela is doing very well lately, and the hospital has moved her out of ICU. She could be home as soon as tomorrow!
UPDATE #2: We had our first media appearance on Friday: local News 10 (ABC) here in Sacramento. We thought it turned out well, so check it out here & please, please, please share it with your networks!
We wrote letters to several decision-makers at Bristol-Myers Squibb pleading for their assistance in providing access to their anti-PD-1 nivolumab.
According to FedEx, our letters arrived yesterday. We’re hoping the physical mail will prompt more of a humanitarian effort than our emails! Send good vibes/prayers/thoughts to BMS’s NYC HQ that those letters help give Mikaela a chance against cancer!
View the letter we sent.
Merck’s should be arriving on Monday, and Genentech’s will be dropped in the mail over the weekend.
If you’d like to help by sending letters of your own, see the information below. Please remember to stay positive and mention that we are interested in either compassionate use or clinical trial opportunities, but there is extreme urgency because her cancer continues to spread while she isn’t receiving any treatment. My contact information is firstname.lastname@example.org & (916) 673-8274.
345 Park Avenue
New York, NY 10154
Michael Giordano, Senior Vice President Head of Oncology and Immunosciences Development
David Berman, Executive Director, Oncology
Andrew Coop, Vice President, Oncology Medical
Fouad Namouni, Vice President, Full Development Lead, Oncology
One Merck Drive
P.O. Box 100
Whitehouse Station, NJ 08889-0100
Kenneth C. Frazier, Chairman of the Board and CEO
Dr. Gary Gilliand, Senior Vice President and Head of Oncology
Eric Rubin, Vice President Oncology Clinical Research
1 DNA Way
South San Francisco, CA 94080
Richard H. Scheller, Ph.D., Executive Vice President, Research & Early Development
Susan Griffing, Sr. Director, Head of Oncology Global Operations
Patricia Moore, VP of Clinical Operations, Research and Early Development